-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bioventus (NYSE:BVS) Trading Down 7.4%
Bioventus (NYSE:BVS) Trading Down 7.4%
Shares of Bioventus Inc. (NYSE:BVS – Get Rating) dropped 7.4% during trading on Thursday . The company traded as low as $7.55 and last traded at $7.66. Approximately 4,531 shares were traded during trading, a decline of 95% from the average daily volume of 82,552 shares. The stock had previously closed at $8.27.
Analyst Ratings Changes
Separately, Morgan Stanley boosted their target price on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Friday, August 12th.
Get Bioventus alerts:Bioventus Stock Performance
The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $603.34 million, a PE ratio of -22.47 and a beta of 2.11. The firm's 50-day simple moving average is $8.01 and its 200-day simple moving average is $9.95.
Bioventus (NYSE:BVS – Get Rating) last announced its quarterly earnings results on Thursday, August 11th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The firm had revenue of $140.33 million during the quarter, compared to analysts' expectations of $140.01 million. Bioventus had a negative net margin of 4.26% and a positive return on equity of 10.35%. During the same quarter in the previous year, the firm posted $0.16 EPS. On average, research analysts predict that Bioventus Inc. will post 0.54 earnings per share for the current year.Institutional Trading of Bioventus
A number of hedge funds have recently added to or reduced their stakes in BVS. Royce & Associates LP raised its holdings in shares of Bioventus by 0.8% in the 2nd quarter. Royce & Associates LP now owns 1,958,785 shares of the company's stock valued at $13,359,000 after purchasing an additional 15,602 shares in the last quarter. Nuance Investments LLC raised its stake in Bioventus by 6.0% in the first quarter. Nuance Investments LLC now owns 1,352,101 shares of the company's stock worth $19,065,000 after buying an additional 77,061 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Bioventus by 49.6% during the second quarter. First Light Asset Management LLC now owns 1,348,460 shares of the company's stock worth $9,196,000 after buying an additional 446,935 shares during the period. Tamarack Advisers LP boosted its position in Bioventus by 82.3% during the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Wasatch Advisors Inc. purchased a new position in shares of Bioventus in the 1st quarter valued at $9,967,000. 44.62% of the stock is owned by hedge funds and other institutional investors.
Bioventus Company Profile
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Bioventus Inc. (NYSE:BVS – Get Rating) dropped 7.4% during trading on Thursday . The company traded as low as $7.55 and last traded at $7.66. Approximately 4,531 shares were traded during trading, a decline of 95% from the average daily volume of 82,552 shares. The stock had previously closed at $8.27.
Bioventus Inc.(紐約證券交易所代碼：BVS-GET評級)的股價在週四的交易中下跌7.4%。該公司股價低至7.55美元，最新報7.66美元。當日成交量約為4,531股，較日均成交量82,552股下降95%。該股此前收盤價為8.27美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, Morgan Stanley boosted their target price on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Friday, August 12th.
另外，摩根士丹利在8月12日(週五)的一份研究報告中將Bioventus的目標價從11.00美元上調至12.00美元，並給予該公司“增持”評級。
Bioventus Stock Performance
Bioventus股票表現
The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $603.34 million, a PE ratio of -22.47 and a beta of 2.11. The firm's 50-day simple moving average is $8.01 and its 200-day simple moving average is $9.95.
該公司的流動比率為1.39，速動比率為1.05，債務權益比率為0.68。該公司市值為6.0334億美元，市盈率為-22.47，貝塔係數為2.11。該公司的50日簡單移動均線切入位為8.01美元，200日簡單移動均線切入位為9.95美元。
Institutional Trading of Bioventus
Bioventus的制度性交易
A number of hedge funds have recently added to or reduced their stakes in BVS. Royce & Associates LP raised its holdings in shares of Bioventus by 0.8% in the 2nd quarter. Royce & Associates LP now owns 1,958,785 shares of the company's stock valued at $13,359,000 after purchasing an additional 15,602 shares in the last quarter. Nuance Investments LLC raised its stake in Bioventus by 6.0% in the first quarter. Nuance Investments LLC now owns 1,352,101 shares of the company's stock worth $19,065,000 after buying an additional 77,061 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Bioventus by 49.6% during the second quarter. First Light Asset Management LLC now owns 1,348,460 shares of the company's stock worth $9,196,000 after buying an additional 446,935 shares during the period. Tamarack Advisers LP boosted its position in Bioventus by 82.3% during the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Wasatch Advisors Inc. purchased a new position in shares of Bioventus in the 1st quarter valued at $9,967,000. 44.62% of the stock is owned by hedge funds and other institutional investors.
一些對衝基金最近增持或減持了BVS的股份。Royce&Associates LP在第二季度將Bioventus的股票持有量增加了0.8%。Royce&Associates LP在上個季度額外購買了15,602股後，現在擁有1,958,785股該公司股票，價值13,359,000美元。Nuance Investments LLC在第一季度將其在Bioventus的持股比例提高了6.0%。Nuance Investments LLC現在擁有1,352,101股該公司股票，價值19,065,000美元，上個季度又購買了77,061股。第一輕資產管理有限責任公司在第二季度增持了49.6%的Bioventus股份。First Light Asset Management LLC在此期間又購買了446,935股，現在擁有1,348,460股該公司股票，價值9,196,000美元。Tamarack Advisers LP在第四季度將其在Bioventus的頭寸提高了82.3%。Tamarack Advisers LP在上個季度增持了395,000股後，現在擁有875,000股該公司股票，價值12,679,000美元。最後，Wasatch Advisors Inc.在第一季度購買了Bioventus的新頭寸，價值996.7萬美元。44.62%的股票由對衝基金和其他機構投資者持有。
Bioventus Company Profile
Bioventus公司簡介
(Get Rating)
(獲取評級)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家醫療設備公司，專注於開發臨牀治療方法並將其商業化，這些治療方法在美國和國際上參與並增強了人體的自然癒合過程。該公司的產品組合包括疼痛治療，其中包括非手術關節疼痛注射療法，以及周圍神經刺激產品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
- 免費獲取StockNews.com關於Bioventus(BVS)的研究報告
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上，Arbor Realty Trust的股息值得嗎？
- 投資者應關注RF Industries
- Netflix可能剛剛觸底的兩個原因
- 3M已經到了壞到好的地步了嗎？
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bioventus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧